Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: Implications for atherosclerotic plaque rupture

Journal of Leukocyte Biology

Volumn 78, Issue 1, 2005, Pages 195-201

  Kim, Min P ^a,b   Zhou, Min ^a   Wahl, Larry M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Angiotensin II receptor subtype 2; Cytokines; Inflammation

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ACETYLSALICYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II [1 SARCOSINE 8 ALANINE]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOMETACIN; INTERSTITIAL COLLAGENASE; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL CULTURE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CORONARY ARTERIOSCLEROSIS; DINOPROSTONE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERTENSION; IMIDAZOLES; MONOCYTES; MYOCARDIAL INFARCTION; OLIGOPEPTIDES; PHOSPHOPROTEIN PHOSPHATASE; PYRIDINES; RECEPTOR, ANGIOTENSIN, TYPE 2; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 22144445977     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1204715     Document Type: Article

References (31)

1. Alderman, M. H., Madhavan, S., Ooi, W. L., Cohen, H., Sealey, J. E., Laragh, J. H. (1991) Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N. Engl. J. Med. 324, 1098-1104.
2. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study investigators. N. Engl. J. Med. 342, 145-153.
3. Weiss, D., Sorescu, D., Taylor, W. R. (2001) Angiotensin II and atherosclerosis. Am. J. Cardiol. 87, 25C-32C.
4. Pratt, R. E. (1999) Angiotensin II and the control of cardiovascular structure. J. Am. Soc. Nephrol. 10 (Suppl. 11), S120-S128.
5. Gomez, R. A., Norling, L. L., Wilfong, N., Isakson, P., Lynch, K. R., Hock, R., Quesenberry, P. (1993) Leukocytes synthesize angiotensinogen. Hypertension 21, 470-475.
6. Kitazono, T., Padgett, R. C., Armstrong, M. L., Tompkins, P. K., Heistad, D. D. (1995) Evidence that angiotensin II is present in human monocytes. Circulation 91, 1129-1134.
7. Ross, R. (1999) Atherosclerosis is an inflammatory disease. Am. Heart J. 138, S419-S420.
8. Potter, D. D., Sobey, C. G., Tompkins, P. K., Rossen, J. D., Heistad, D. D. (1998) Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 98, 800-807.
9. Kintscher, U., Wakino, S., Kim, S., Fleck, E., Hsueh, W. A., Law, R. E. (2001) Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension 37, 587-593.
10. Keidar, S., Heinrich, R., Kaplan, M., Hayek, T., Aviram, M. (2001) Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler. Thromb. Vasc. Biol. 21, 1464-1469.
11. Sukhova, G. K., Schonbeck, U., Rabkin, E., Schoen, F. J., Poole, A. R., Billinghurst, R. C., Libby, P. (1999) Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99, 2503-2509.
12. Plenz, G., Koenig, C., Severs, N. J., Robenek, H. (1997) Smooth muscle cells express granulocyte-macrophage colony-stimulating factor in the undiseased and atherosclerotic human coronary artery. Arterioscler. Thromb. Vasc. Biol. 17, 2489-2499.
13. Frostegard, J., Ulfgren, A. K., Nyberg, P., Hedin, U., Swedenborg, J., Andersson, U., Hansson, G. K. (1999) Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 145, 33-43.
14. Young, J. L., Libby, P., Schonbeck, U. (2002) Cytokines in the pathogenesis of atherosclerosis. Thromb. Haemost. 88, 554-567.
15. Zhang, Y., McCluskey, K., Fujii, K., Wahl, L. M. (1998) Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-α, granulocyte-macrophage CSF, and IL-1 β through prostaglandin-dependent and -independent mechanisms. J. Immunol. 161, 3071-3076.
16. Zhou, M., Zhang, Y., Ardans, J. A., Wahl, L. M. (2003) Interferon-γ differentially regulates monocyte matrix metalloproteinase-1 and -9 through tumor necrosis factor-α and caspase 8. J. Biol. Chem. 278, 45406-45413.
17. Kim, M. P., Gaydos, C. A., Wood, B. J., Hardick, J. P., Zhang, Y., Wahl, L. M. (2005) Chlamydia pneumoniae enhances cytokine-stimulated human monocyte matrix metalloproteinases through a prostaglandin E2-dependent mechanism. Infect. Immun. 73, 632-634.
18. Kuo, C. C., Gown, A. M., Benditt, E. P., Grayston, J. T. (1993) Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler. Thromb. 13, 1501-1504.
19. Kuo, C. C., Grayston, J. T., Campbell, L. A., Goo, Y. A., Wissler, R. W., Benditt, E. P. (1995) Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc. Natl. Acad. Sci. USA 92, 6911-6914.
20. Kuo, C. C., Shor, A., Campbell, L. A., Fukushi, H., Patton, D. L., Gravston, J. T. (1993) Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J. Infect. Dis. 167, 841-849.
21. Galis, Z. S., Sukhova, G. K., Lark, M. W., Libby, P. (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493-2503.
22. Shankavaram, U. T., Lai, W. C., Netzel-Arnett, S., Mangan, P. R., Ardans, J. A., Caterina, N., Stetler-Stevenson, W. G., Birkedal-Hansen, H., Wahl, L. M. (2001) Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin- dependent regulation and role in metalloproteinase-2 activation. J. Biol. Chem. 276, 19027-19032.
23. Zisman, L. S., Asano, K., Dutcher, D. L., Ferdensi, A., Robertson, A. D., Jenkin, M., Bush, E. W., Bohlmeyer, T., Perryman, M. B., Bristow, M. R. (1998) Differential regulation of cardiac angiotensin-converting enzyme binding sites and ATI receptor density in the failing human heart. Circulation 98, 1735-1741.
24. Cote, F., Do, T. H., Laflamme, L., Gallo, J. M., Gallo-Payet, N. (1999) Activation of the AT(2) receptor of angiotensin II induces neurite outgrowth and cell migration in microexplant cultures of the cerebellum. J. Biol. Chem. 274, 31686-31692.
25. Kouwenhoven, M., Ozenci, V., Teleshova, N., Hussein, Y., Huang, Y. M., Eusebio, A., Link, H. (2001) Enzyme-linked immunospot assays provide a sensitive tool for detection of cytokine secretion by monocytes. Clin. Diagn. Lab. Immunol. 8, 1248-1257.
26. Krishnaswamy, G., Kelley, J., Yerra, L., Smith, J. K., Chi, D. S. (1999) Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J. Interferon Cytokine Res. 19, 91-104.
27. Pfeffer, M. A., Braunwald, E., Moye, L. A., Basta, L., Brown Jr., E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N. Engl. J. Med. 327, 669-677.
28. de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., Unger, T. (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472.
29. Matsubara, H. (1998) Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ. Res. 83, 1182-1191.
30. Cipollone, F., Fazia, M., Iezzi, A., Pini, B., Cuccurullo, C., Zucchelli, M., de Cesare, D., Ucchino, S., Spigonardo, F., De Luca, M., Muraro, R., Bei, R., Bucci, M., Cuccurullo, F., Mezzetti, A. (2004) Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 109, 1482-1488.
31. Buring, J. E., Hennekens, C. H. (1990) Prevention of cardiovascular disease: risks and benefits of aspirin. J. Gen. Intern. Med. 5, S54-S57.